Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The application of MSC-derived secretome has been studied towards different pathologies by counteracting inflammation while inducing tissue regeneration namely in lung, hepatic and brain tissues.”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [160]
In the citing paper
“Nevertheless, this cell-free approach has also been reported with beneficial effects for other pathologies, including bone tissue, cardiovascular, intestinal and renal diseases [158], [159], [160], [161], [162], [163], [164], [165], [166], [167], [168], [169], [170] (Table 2).”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [160]
Citations
Cites
Bone marrow cells regenerate infarcted myocardium
Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D. M., et al. (2001) · Nature · doi:10.1038/35070587 · Cited by 5,155
Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart
Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002) · Circulation · doi:10.1161/hc0102.101442 · Cited by 2,234
Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells
Jackson, K. A., Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., & Goodell, M. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12150 · Cited by 1,960
Mangi, A. A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J. S., & Dzau, V. J. (2003) · Nature Medicine · doi:10.1038/nm912 · Cited by 1,509
Self-citationKajstura, J., Cheng, W. N., Krzysztof Reiss, F., CLARK, W. A., Sonnenblick, E. H., Krajewski, S., Reed, J., Olivetti, G., & Anversa, P. (1996) · PubMed · Cited by 1,039
Nygren, J. M., Jovinge, S., Breitbach, M., Säwén, P., Röll, W., Hescheler, J., Taneera, J., Fleischmann, B. K., & Jacobsen, S. E. W. (2004) · Nature Medicine · doi:10.1038/nm1040 · Cited by 1,037
Friedrich, J. O., Apstein, C. S., & Ingwall, J. S. (1995) · Circulation · doi:10.1161/01.cir.92.12.3527 · Cited by 43
Self-citation
Research works printed but not linked: 3
- Tomita, S. et al. Circulation 100 (19 Suppl), II247–56 (1999).
- Gnecchi, M. et al. Circulation 110 (17 Suppl), III249 (2004).
- Kajstura, J. et al. Lab. Invest. 74, 86–107 (1996).
Cited by
Items 501–600 of 1,000
The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models
Maleiner, B., Tomasch, J., Heher, P., Spadiut, O., Rünzler, D., & Fuchs, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01130 · Cited by 63
“, 2012) including Interleukin (IL)-6, IL-10, stromal cell-derived factor (Gnecchi et al., 2005; Kortesidis et al., 2005; Zhang et al., 2007; Yin et al., 2011), vascular endothelial growth factor, fibroblast growth factor (FGF), IL-1, matrix metalloproteinases (MMPs), platelet derived growth factor, transforming growth…”
BackgroundZhang, Y., Li, Y., Li, W., Cai, J., Yue, M., Jiang, L., Xu, R., Zhang, L., Li, J., & Zhu, C. (2018) · Stem Cells International · doi:10.1155/2018/7159465 · Cited by 65
“Furthermore, inhibition of cell death is one therapeutic basis of MSC therapy that has been observed in models of myocardial infarction and stroke [28, 29].”
BackgroundSelf-citationSingla, D. K., Singla, R. D., & McDonald, D. E. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00279.2008 · Cited by 60
“Importantly, these studies suggest that autocrine or paracrine factors released in the heart following ES or adult stem cell transplantation inhibit host myocardium apoptosis (14, 15, 41).”
BackgroundThe Role of Tissue Engineering and Biomaterials in Cardiac Regenerative Medicine
Zhao, Y., Feric, N. T., Thavandiran, N., Nunes, S. S., & Radisic, M. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.08.027 · Cited by 63
“delineated in mechanistic pre-clinical studies (23, 24).”
Cunnane, E. M., Weinbaum, J. S., O’Brien, F. J., & Vorp, D. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00086 · Cited by 62
Regenerative Cardiovascular Therapies: Stem Cells and Beyond
Wernly, B., Mirna, M., Rezar, R., Prodinger, C. M., Jung, C., Podesser, B. K., Kiss, A., Hoppe, U. C., & Lichtenauer, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061420 · Cited by 60
“This is of particular interest as in vitro data showed a reduction of hypoxia-induced rat cardiomyocyte cell death after addition of conditioned, cell-free, mesenchymal stem cell medium [30,31].”
BackgroundAge-dependent impairment of adipose-derived stem cells isolated from horses
Alicka, M., Kornicka‐Garbowska, K., Kucharczyk, K., Kępska, M., Röcken, M., & Marycz, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1512-6 · Cited by 93
“The fact suggests that paracrine soluble factors produced and secreted by MSCs have a specific responsibility for tissue repairing [7, 8].”
BackgroundSTEM CELL MECHANISMS AND PARACRINE EFFECTS
Crisostomo, P. R., Wang, M., Markel, T. A., Lahm, T., Abarbanell, A. M., Herrmann, J. L., & Meldrum, D. R. (2007) · Shock · doi:10.1097/shk.0b013e318058a817 · Cited by 59
“In further support of differentiation-independent cardioprotection, in vitro studies of cardiomyocytes injured in response to monocyte chemoattractant protein 1 (12) or hypoxia (13) also demonstrated protection”
BackgroundResultLin, H., Shabbir, A., Molnar, M., Yang, J., Marion, S. M., Canty, J. M., & Lee, T. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21414 · Cited by 60
“Combined gene and stem cell applications have been found to boost the therapeutic potential of adult stem cells (Iwaguro et al., 2002; Gnecchi et al., 2006; Wang et al., 2006).”
BackgroundXu, J., Xiong, Y.-Y., Li, Q., Hu, M.-J., Huang, P.-S., Xu, J.-Y., Tian, X.-Q., Chen, J., Liu, J.-D., Li, Q., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0013 · Cited by 62
Immune Plasticity of Bone Marrow-Derived Mesenchymal Stromal Cells
Stagg, J., & Galipeau, J. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68976-8_3 · Cited by 62
“In a recent issue of Nature Medicine, Victor Dzau’s group provided evidence in support of this hypothesis ( Gnecchi et al. 2005 ).”
BackgroundZhang, Y., Zhang, R., Li, Y., He, G., Zhang, D., & Zhang, F. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-0737-y · Cited by 58
“Furthermore, it has been shown that their functional benefit was originally attributed to their differentiation ability and paracrine effects [28–30].”
BackgroundMesenchymal stromal cells (MSCs): science and f(r)iction
Bieback, K., Wuchter, P., Besser, D., Franke, W. W., Becker, M., Ott, M., Pacher, M., Ma, N., Stamm, C., Klüter, H., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0915-y · Cited by 64
“stimulate survival and proliferation of endogenous cells in the injured tissue and increase angiogenesis [43–45].”
BackgroundPaul, D., Samuel, S. M., & Maulik, N. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2455 · Cited by 58
“Paracrine effectors are the major players through which the engrafted MSCs exert their beneficial effects (43, 46, 77, 82, 92, 117, 138).”
Protein Signaling Networks from Single Cell Fluctuations and Information Theory Profiling
Shin, Y. S., Remacle, F., Fan, R., Hwang, K., Wei, W., Ahmad, H. M. N., Levine, R. D., & Heath, J. R. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.04.025 · Cited by 61
Foo, K. S., Lehtinen, M. L., Leung, C. Y., Lian, X. L., Xu, J., Keung, W., Geng, L., Kolstad, T. R., Thams, S., Wong, A. O.-T., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.012 · Cited by 65
“, stress endurance.(42,43) Defining these factors and combining them within the HVPs via modified RNA (modRNA) technology will become of interest to further improve the maturation,”
BackgroundImproved therapeutic potential of MSCs by genetic modification
Wei, W., Huang, Y., Li, D., Gou, H., & Wang, W. (2018) · Gene Therapy · doi:10.1038/s41434-018-0041-8 · Cited by 63
Komura, S., Satake, T., Goto, A., Aoki, H., Shibata, H., Ito, K., Hirakawa, A., Yamada, Y., & Akiyama, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61063-6 · Cited by 62
Zhang, S., Yang, Y., Fan, L., Zhang, F., & Li, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.218 · Cited by 56
“CM contained paracrine soluble factors and extracellular vesicles (EVs) promoting tissue repair and regeneration (64).”
BackgroundImmune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells
Tolar, J., Hippen, K. L., & Blazar, B. R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07781.x · Cited by 64
“In addition, MSCs can be genetically modified to enhance their tissue repair and cross-correction abilities (Bartholomew et al, 2001; Gnecchi et al, 2005; Egermann et al, 2006).”
Backgroundde la Fuente, L. M., Stertzer, S. H., Argentieri, J. C., Peñaloza, E., Miano, J. A., Koziner, B., Bilos, C., & Altman, P. A. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.04.051 · Cited by 61
Kindi, A. H. A., Asenjo, J. F., Ge, Y., Chen, G. Y., Bhathena, J., Chiu, R. C. ‐., Prakash, S., & Shum‐Tim, D. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.03.066 · Cited by 57
“Different studies have, in turn, implicated the role of transdifferentiation [17], cellular fusion [18], and paracrine effects [19] as the main mechanisms behind such improvements.”
Fuster-Matanzo, A., Gessler, F., Leonardi, T., Iraci, N., & Pluchino, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0232-9 · Cited by 56
“function by reducing the rate of apoptosis [25, 26].”
BackgroundRegenerative Medicine for Equine Musculoskeletal Diseases
Ribitsch, I., Oreff, G. L., & Jenner, F. (2021) · Animals · doi:10.3390/ani11010234 · Cited by 64
Lee, C.-S., Fan, J., Hwang, H. S., Kim, S., Chen, C., Kang, M., Aghaloo, T. L., James, A. W., & Lee, M. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04159 · Cited by 57
Davies, B., Elwood, N. J., Li, S., Cullinane, F., Edwards, G. A., Newgreen, D. F., & Brizard, C. P. (2010) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.10.035 · Cited by 57
Alginate Scaffolds for Mesenchymal Stem Cell Cardiac Therapy: Influence of Alginate Composition
Ceccaldi, C., Fullana, S. G., Alfarano, C., Lairez, O., Calise, D., Cussac, D., Parini, A., & Sallerin, B. (2012) · Cell Transplantation · doi:10.3727/096368912x647252 · Cited by 60
“extension at the injury site and promote blood supply (9,12,17,25).”
BackgroundEmpowering Adult Stem Cells for Myocardial Regeneration V2.0: Success in Small Steps
Broughton, K. M., & Sussman, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.305227 · Cited by 59
“An early account of secretome released promoting beneficial effects was reported as a byproduct of MSCs genetically modified to overexpress AKT, which reduced infarct size and cardiomyocyte apoptosis in an adult rat model, as compared with controls of nonmodified MSC.(66) Another early account of the beneficial byprod…”
BackgroundInfluentialShi, Y., Shi, H., Nomi, A., Zhang, L., ZHANG, B., & Qian, H. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.012 · Cited by 59
Self-citationParacrine Effects of Cell Transplantation: Strategies to Augment the Efficacy of Cell Therapies
Cheng, A. S., & Yau, T. M. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.04.003 · Cited by 61
Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia
Erwin, G. S., Crisostomo, P. R., Wang, Y., Wang, M., Markel, T. A., Guzman, M., Sando, I. C., Sharma, R. A., & Meldrum, D. R. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.02.006 · Cited by 57
Wang, Q., Guo, W., Niu, L., Zhou, Y., Wang, Z., Chen, J., Chen, J., Ma, J., Zhang, J., Jiang, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202404064 · Cited by 71
Regenerating functional heart tissue for myocardial repair
Alcon, A., Çağavi, E., & Qyang, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0942-4 · Cited by 58
“Other paracrine signaling candidates include fibroblast growth factor [54], insulin-like growth factor, and stromal-derived growth factor [55].”
Lee, E. J., Choi, E., Kang, S. K., Kim, G.-H., Park, J. Y., Kang, H., Lee, S.-W., Kim, K.-H., Kwon, J. S., Lee, K. H., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.202 · Cited by 60
What Is the Oncologic Risk of Stem Cell Treatment for Heart Disease?
Hatzistergos, K. E., Blum, A., Ince, T. A., Grichnik, J. M., & Hare, J. M. (2011) · Circulation Research · doi:10.1161/circresaha.111.246611 · Cited by 56
Madonna, R., Petrov, L., Teberino, M. A., Manzoli, L., Karam, J., Renna, F. V., Ferdinándy, P., Montero‐Menei, C. N., Ylä‐Herttuala, S., & Caterina, R. D. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv197 · Cited by 56
Alvino, V. V., Fernández‐Jiménez, R., Rodríguez-Arabaolaza, I., Slater, S. C., Mangialardi, G., Avolio, E., Spencer, H., Culliford, L. A., Hassan, S., Ballesteros, L. S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006727 · Cited by 59
Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges
Peltzer, J., Aletti, M., Frescaline, N., Busson, É., Lataillade, J., & Martinaud, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02013 · Cited by 56
“It had already been demonstrated that BMMSCs could have a benefit on fibrosis development in different organs including: lung (62), kidney (63), heart (32) or skin (64).”
BackgroundZhang, E., Yang, Y., Chen, S., Peng, C., Lavin, M. F., Yeo, A. J., Li, C. R., Liu, X., Guan, Y., Du, X., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1045-4 · Cited by 56
Numasawa, Y., Kimura, T., Miyoshi, S., Nishiyama, N., Hida, N., Tsuji, H., Tsuruta, H., Segawa, K., Ogawa, S., & Umezawa, A. (2011) · Stem Cells · doi:10.1002/stem.691 · Cited by 55
Rupp, S., Zeiher, A. M., Dimmeler, S., Tonn, T., Bauer, J. M., Jux, C., Akintuerk, H., & Schranz, D. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.10.006 · Cited by 55
Protective paracrine effect of mesenchymal stem cells on cardiomyocytes
Xiang, M., He, A., Wang, J.-A., & Gui, C. (2009) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0920153 · Cited by 55
Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier
Poomani, M. S., Mariappan, I., Perumal, R., Regurajan, R., Muthan, K., & Subramanian, V. (2022) · Global Heart · doi:10.5334/gh.1098 · Cited by 60
Wang, Y., Abarbanell, A. M., Herrmann, J. L., Weil, B. R., Manukyan, M. C., Poynter, J. A., & Meldrum, D. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014206 · Cited by 54
“Although it is well established that MSC exert a protective role in hearts following acute ischemia and reperfusion (I/R) injury [3,5,15,17,26], it is unknown whether knock-out of TLR4 will increase MSC-mediated cardioprotection.”
BackgroundInfluentialZhu, X., He, B., Zhou, X., & Ren, J. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1524-3 · Cited by 58
“Gnecchi et al. (2005) have reported the production and progressive increase of IL-10 at 1 h after the injection of C3H/HeJ mice with ConA.”
BackgroundInfluentialKim, S.-W., Jin, H. L., Kang, S., Kim, S., Yoo, K., Jang, Y., Kim, H. O., & Yoon, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.110 · Cited by 57
“Many studies have reported that paracrine or humoral effects are a major therapeutic mechanism of these EPC or MSC in cardiovascular regeneration [5, 13, 32, 34].”
Wang, X., Takagawa, J., Lam, V. C., Haddad, D. J., Tobler, D. L., Mok, P. Y., Zhang, Y., Clifford, B. T., Pinnamaneni, K., Saini, S. A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002814 · Cited by 58
Visualization of exosomes from mesenchymal stem cells in vivo by magnetic resonance imaging
Liu, T., Zhu, Y., Zhao, R., Wei, X., & Xin, X. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.02.001 · Cited by 55
Song, Y.-S., Joo, H.-W., Park, I.-H., Shen, G.-Y., Lee, Y., Shin, J. H., Kim, H., & Kim, K.-S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179972 · Cited by 53
Chen, K., Li, Y., Xu, L., Qian, Y., Liu, N., Zhou, C., Liu, J., Zhou, L., Xu, Z., Jia, R., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02921-0 · Cited by 53
“Some studies have demonstrated the consistency of the therapeutic effect of cardiac transplant cells without engraftment, indicating that paracrine mechanisms could potentially be used for therapeutic effects [129, 130].”
BackgroundTertel, T., Dittrich, R., Arsène, P., Jensen, A., & Giebel, B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1282860 · Cited by 53
Templin, C., Lscher, T. F., & Landmesser, U. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103219ct · Cited by 56
“Moreover, the injection of conditioned medium from MSCs results in the improvements of left ventricular function and reduced apoptosis (Gnecchi et al. 2005).”
BackgroundShinmura, D., Togashi, I., Miyoshi, S., Nishiyama, N., Hida, N., Tsuji, H., Tsuruta, H., Segawa, K., Tsukada, Y., Ogawa, S., et al. (2010) · Stem Cells · doi:10.1002/stem.574 · Cited by 58
Hacker, S., Mittermayr, R., Nickl, S., Haider, T. T., Lebherz-Eichinger, D., Beer, L., Mitterbauer, A., Leiss, H., Zimmermann, M., Schweiger, T., et al. (2016) · Scientific Reports · doi:10.1038/srep25168 · Cited by 53
Applications of stem cell-derived exosomes in tissue engineering and neurological diseases
Sun, B., Peng, J. C., Wang, S., Liu, X., Zhang, K., Zhang, Z., Wang, C., Jing, X., Zhou, C., & Wang, Y. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0059 · Cited by 55
Isolation and expansion of resident cardiac progenitor cells
Vliet, P. P. V., Sluijter, J. P. G., Doevendans, P. A., & Goumans, M. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.1.33 · Cited by 53
Schiekofer, S., Shiojima, I., Sato, K., Galasso, G., Oshima, Y., & Walsh, K. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00234.2005 · Cited by 53
Ebert, A., Diecke, S., Chen, I. Y., & Wu, J. C. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201504395 · Cited by 54
“However, to a large extent, functional improvement in left ventricular ejection fraction (LVEF) in some of these transplantation models has been suggested to result through the release of paracrine factors EMBO Molecular Medicine Vol 7 | No 9 | 2015 ª 2015 The Authors (Gnecchi et al, 2005; Gu et al, 2012; Huber et al,…”
BackgroundInfluentialMechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy
Kelkar, A. A., Butler, J., Schelbert, E. B., Greene, S. J., Quyyumi, A. A., Bonow, R. O., Cohen, I. S., Gheorghiade, M., Lipinski, M. J., Sun, W., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.010 · Cited by 53
Paracrine Effects of Mesenchymal Stem Cells in Ischemic Stroke: Opportunities and Challenges
Taei, A. A., Khodabakhsh, P., Nasoohi, S., Farahmandfar, M., & Dargahi, L. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02967-4 · Cited by 58
“which demonstrated that therapeutic potentials of MSCs are mediated by the release of secretory molecules [50].”
BackgroundAntiarrhythmic Potential of Mesenchymal Stem Cell Is Modulated by Hypoxic Environment
Hwang, H. J., Chang, W., Song, B., Song, H., Cha, M., Kim, I.-K., Lim, S., Choi, E. J., Ham, O., Lee, S.-Y., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.056 · Cited by 52
Mononuclear cell secretome protects from experimental autoimmune myocarditis
Höetzenecker, K., Zimmermann, M., Hoetzenecker, W., Schweiger, T., Kollmann, D., Mildner, M., Hegedűs, B., Mitterbauer, A., Hacker, S., Birner, P., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs459 · Cited by 52
“mediated via paracrine signalling than by direct cellular interactions.(7) Conditioned culture medium containing the secretome of mesenchymal stem cells is rich in angiogenic and chemotactic factors.”
BackgroundThe Advantages and Disadvantages of Sfrp1 and Sfrp2 Expression in Pathological Events
Esteve, P., & Bovolenta, P. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.11 · Cited by 49
Paracrine Effects of Cell Transplantation: Modifying Ventricular Remodeling in the Failing Heart
Fedak, P. W. M. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.04.001 · Cited by 54
Gao, L., Yi, M., Xing, M., Li, H., Zhou, Y., Xu, Q., Zhang, Z., Wen, Z., & Chang, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01320j · Cited by 52
Man, K., Brunet, M. Y., Federici, A., Hoey, D. A., & Cox, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.829969 · Cited by 53
Luo, Y., Wang, Y., Poynter, J. A., Manukyan, M. C., Herrmann, J. L., Abarbanell, A. M., Weil, B. R., & Meldrum, D. R. (2011) · Surgery · doi:10.1016/j.surg.2011.09.033 · Cited by 51
“Accumulated evidence has shown that one of the primary mechanisms of MSC-mediated myocardial protection from ischemia is through the paracrine effects of growth factors released by MSC that promote cell proliferation and survival, inhibit apoptosis and enhance angiogenesis.(14) VEGF has been shown to enhance myocardia…”
BackgroundBadimón, L., Oñate, B., & Vilahur, G. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.02.025 · Cited by 55
Impact of mesenchymal stem cells’ secretome on glioblastoma pathophysiology
de Castro, J. V., Gomes, E. D., Granja, S., Anjo, S. I., Baltazar, F., Manadas, B. J., Salgado, A. J., & Costa, B. M. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1303-8 · Cited by 51
Huang, J., Kin Pong, U., Yang, F., Ji, Z., Lin, J., Weng, Z., Tsang, L. L., Merson, T. D., Ruan, Y. C., Wan, C., et al. (2021) · Theranostics · doi:10.7150/thno.57234 · Cited by 51
“Although the cellular and molecular mechanisms underlying the beneficial effects of MSCs are largely unknown, it has become evident that the reparative activities of MSCs are mainly associated with their paracrine effects [10].”
BackgroundUrokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells
Vallabhaneni, K. C., Tkachuk, S., Kiyan, Y., Shushakova, N., Haller, H. G., Dumler, I., & Eden, G. C. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq362 · Cited by 51
“studies and clinical trials for cardiac regeneration therapy after postmyocardial infarction, intramyocardial injection or intravenous administration of autologous MSCs increased vasculogenesis and improved cardiac function.(29,30) Other interesting studies reported the potential of MSCs to contribute to atheroscleros…”
BackgroundCombining stem cells in myocardial infarction: The road to superior repair?
Beliën, H., Evens, L., Hendrikx, M., Bito, V., & Bronckaers, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21839 · Cited by 52
“Furthermore, it is suggested that Akt plays a role in cytoprotecting cardiomyocytes exposed to hypoxia, thereby further supporting the “paracrine hypothesis” of myocardial repair by stem cells.(87) MSCs not only act by producing proregenerative paracrine factors, but also have immunomodulatory properties by interactin…”
BackgroundAtoui, R., Asenjo, J. F., Duong, M., Chen, G., Chiu, R. C., & Shum‐Tim, D. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.10.034 · Cited by 58
Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction
Vassalli, G., & Moccetti, T. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13209 · Cited by 56
Strategies and Challenges to Myocardial Replacement Therapy
Feric, N. T., & Radisic, M. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0288 · Cited by 47
Cardiosphere-Derived Cells and Ischemic Heart Failure
Ashur, C., & Frishman, W. H. (2017) · Cardiology in Review · doi:10.1097/crd.0000000000000173 · Cited by 52
“In vivo, when this MSC hypoxic-conditioned medium was injected directly into postinfarct myocardium, there was a decrease in infarct size and an overall improvement in ventricular function.(108) Taken together, these suggest a paracrine role of progenitor cells that triggers endogenous cell proliferation via soluble m…”
BackgroundMethodInfluentialCiuffreda, M. C., Malpasso, G., Chokoza, C., Bezuidenhout, D., Goetsch, K. P., Mura, M., Pisano, F., Davies, N. H., & Gnecchi, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.01.005 · Cited by 51
Self-citationEngineering pro-angiogenic biomaterials via chemoselective extracellular vesicle immobilization
Xing, Y., Yerneni, S. S., Wang, W., Taylor, R. E., Campbell, P. G., & Ren, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121357 · Cited by 52
Regenerative therapy for cardiovascular disease
Pfister, O., Verde, G. D., Liao, R., & Kuster, G. M. (2013) · Translational research · doi:10.1016/j.trsl.2013.12.005 · Cited by 51
Mocchi, M., Bari, E., Marrubini, G., Bonda, A. F., Perteghella, S., Tartara, F., Cofano, F., Perna, G. D., Giovannelli, L., Mandracchia, D., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081129 · Cited by 49
Sarkissian, S. D., Lévesque, T., & Noiseux, N. (2017) · World Journal of Stem Cells · doi:10.4252/wjsc.v9.i1.9 · Cited by 54
Self-citationNeovascularization: The Main Mechanism of MSCs in Ischemic Heart Disease Therapy
Shi, W., Xin, Q., Yuan, R., Yuan, Y., Cong, W., & Chen, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.633300 · Cited by 50
“They found genetically modified BMSCs overexpressing the Akt1 released paracrine factors that exert cytoprotective effects on cardiomyocytes exposed to hypoxia and limited infarct size and improved ventricular function (27, 28).”
BackgroundBari, E., Scocozza, F., Perteghella, S., Sorlini, M., Auricchio, F., Torre, M. L., & Conti, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040515 · Cited by 49
“However, 20 years after their discovery, in 2010, Caplan suggested renaming MSCs as “medicinal signaling cells” since their multipotency seemed not to be the only therapeutic aspect [4,5].”
BackgroundSánchez-Sánchez, R., Gómez-Ferrer, M., Reinal, I., Buigues, M., Villanueva-Bádenas, E., Ontoria‐Oviedo, I., Martínez, A. H., González‐King, H., Peiró-Molina, E., Dorronsoro, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.734143 · Cited by 49
Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans
Kubal, C. A., Sheth, K., Nadal‐Ginard, B., & Galiñanes, M. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.06.028 · Cited by 49
Søndergaard, C. S., Hess, D. A., Maxwell, D. J., Weinheimer, C. J., Rosová, I., Creer, M. H., Piwnica-Worms, D. R., Kovács, A. D., Pedersen, L., & Nolta, J. A. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-24 · Cited by 49
“The present results are thus more in line with our previous results and recent reports on the role of donor hematopoietic cells in the regeneration of damaged tissue [17,26-28].”
ResultVogel, S., Chatterjee, M., Metzger, K., Borst, O., Geisler, T., Seizer, P., Müller, I. I., Mack, A. F., Schumann, S., Bühring, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530287 · Cited by 49
“Although stem cell-based therapy for the treatment of myocardial ischemia and infarction is still in its preliminary phase, it has the potential to beneficially affect ventricular remodeling and significantly improve heart function (12, 17, 18, 47).”
BackgroundMesenchymal Stem Cell Therapy for Protection and Repair of Injured Vital Organs
van Poll, D., Parekkadan, B., Rinkes, I. H. M. B., Tilles, A. W., & Yarmush, M. L. (2008) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-008-0001-2 · Cited by 55
Wingate, K., Floren, M. L., Tan, Y., Tseng, P.-O., & Tan, W. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0249 · Cited by 58
“We have shown that simultaneous regulation of biochemical and biomechanical factors in vitro is an effective way to quickly perpetuate the differentiation of MSCs into cells that express both mature and functional endothelial markers (Flt, vWF, PECAM, and eNOS) of vascular ECs.”
InfluentialZhang, X., Hu, M.-G., Pan, K., Li, C.-H., & Liu, R. (2016) · Stem Cells International · doi:10.1155/2016/4626073 · Cited by 47
Li, Z., Wang, Y., Wang, H.-J., Wu, J.-H., & Tan, Y. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-09952-1 · Cited by 52
Wang, L., Wei, J., Ferreira, A. D. F., Wang, H., Zhang, L., Zhang, Q., Bellio, M. A., Chu, X., Khan, A., Jayaweera, D. T., et al. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.08.005 · Cited by 48
Self-citationCui, X., Wang, H., Guo, H.-D., Wang, C., Ao, H., Liu, X., & Tan, Y. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.220.139 · Cited by 48
“Akt and other possible cell survival pathways may be rapidly activated by DZ-pretreated SMSCs in MI model (Gnecchi et al. 2005).”
BackgroundLan, Y., Xie, H., Jin, Q., Zhao, X., Shi, Y., Zhou, Y., Hu, Z., Ye, Y., Huang, X., Sun, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.019 · Cited by 52
Mesenchymal Stromal Cells: Heterogeneity and Therapeutical Applications
Ouzin, M., & Kogler, G. (2023) · Cells · doi:10.3390/cells12162039 · Cited by 42
“Moreover, the immunomodulatory effects of BM-MSCs were used for treatment of patients suffering from ischemic injury in numerous clinical trials and have been proved to be beneficiary [61].”
BackgroundPeng, Y., Huang, S., Wu, Y. L., Cheng, B., Nie, X., Liu, H., Ma, K., Zhou, J., Gao, D., Feng, C., et al. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0064 · Cited by 53
Stem Cell-Based Cardiac Tissue Engineering
Nunes, S. S., Song, H. W., Chiang, C. K., & Radisic, M. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9307-x · Cited by 51
“The fact that some improvement in function is observed regardless of the cell type injected and that cell retention is very small, indicates that improvement in cardiac function is likely due to the secretion of paracrine factors by the injected cells [25, 26] resulting in an increased preservation of affected myocard…”
BackgroundWang, N., Shao, Y., Mei, Y., Zhang, L., Li, Q., Li, D., Shi, S., Hong, Q., Lin, H., & Chen, X. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt142 · Cited by 53
“Researchers believe that the effect is mediated by an increase in mitogenic [6], anti-inflammatory, anti-apoptotic, immunosuppressive and anti-fibrogenic factors [2,7], as well as differentiation into specific cells [8].”
BackgroundSelf-citationCombining angiogenic gene and stem cell therapies for myocardial infarction
Pons, J., Huang, Y., Takagawa, J., Arakawa-Hoyt, J. S., Ye, J., Grossman, W., Kan, Y. W., & Su, H. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1362 · Cited by 51
Lai, R. C., Yeo, R. W. Y., Padmanabhan, J., Choo, A. B. H., de Kleijn, D. P. V., & Lim, S. K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3584-0_29 · Cited by 49
Metadata
- Authors
- Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., & Dzau, V. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Dzau, Victor J
- ORCID
- Venue
- Nature Medicine
- Published
- 2005-04
- Volume
- 11
- Issue
- 4
- Pages
- 367-368
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2067591094
- Cited by
- 1,677
- References
- 7
- Citations by year
- 2026: 31 · 2025: 35 · 2024: 49 · 2023: 55 · 2022: 67 · 2021: 86 · 2020: 91 · 2019: 69 · 2018: 74 · 2017: 87 · 2016: 95 · 2015: 89 · 2014: 81 · 2013: 88 · 2012: 106
- FWCI
- 38.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (1z01hl005320-01)
- National Heart, Lung, and Blood Institute (HL 73219, HL-58516, HL 72010, R01HL063985, HL 5320, R01HL058516, R01HL072010, HL-35610, R01HL073219, HL 63985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- paracrine signaling, mesenchymal stem cells, Akt signaling, myocardial ischemia, cardioprotection, cell therapy, exosomes, secretome
- MeSH terms
- Animals, Cells, Cultured, Myocardial Infarction, Myocardium, Proto-Oncogene Proteins, Cell Hypoxia, Bone Marrow Transplantation, Culture Media, Conditioned, Apoptosis, Protein Serine-Threonine Kinases, Intercellular Signaling Peptides and Proteins, Mesenchymal Stem Cell Transplantation, Green Fluorescent Proteins, Proto-Oncogene Proteins c-akt, Rats, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.